Tomohiko Harada

Mr. Tomohiko Harada

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 May 2025 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
THTomohiko Harada
Tomohiko Harada
EUEiseki Usami
Eiseki Usami
TATakuya Aso
Takuya Aso
NYNatsumi Yokoyama
Natsumi Yokoyama
YIYukari Imanishi
Yukari Imanishi
TYTomoaki Yoshimura
Tomoaki Yoshimura
Introduction: Numerous injectable anticancer drugs are administered at varying doses based on the body surface area and weight of the patients, often resulting in a certain volume of residual medication. Several anticancer drugs are expensive, thus, their increased use has led to a corresponding increase in drug waste and healthcare costs. Two potential solutions to this issue include drug vial optimization (DVO) and dose rounding (DR). However, DR has rarely been implemented in Japan. Here, we evaluated DVO and DR to assess whether DR could be a viable strategy to reduce the number of anticancer drugs discarded and minimize drug-related costs in Japan. Methods: Patients who received bevacizumab, ramucirumab, gemcitabine, or levofolinate between January and December 2023 at Kanagawa Prefectural Ashigarakami Hospital (Ashigarakami) and Ogaki Municipal Hospital (Ogaki) were included in this study. Actual quantities used for each anticancer drug were extracted from electronic medical records, and the quantities used of drugs during the application of DVO and DR were calculated. Based on these findings, we estimated the reduction in drug waste and the associated cost savings for DVO and DR. Results: DR was more effective than DVO in minimizing the waste of drugs, with 0% waste for gemcitabine at Ogaki and 0% waste for levofolinate at both institutions. Conclusion: Compared with DVO, DR is not influenced by the number of patients treated or the volume of anticancer drugs administered, making it feasible for implementation across a wide range of institutions and a highly effective strategy for minimizing waste. DR should be advocated as a key approach for reducing drug costs in Japan in the future.

29 September 2026 in Current Oncology
Verified
Journal Article
Open access
PDF file
TSTomoya Sugimoto
Tomoya Sugimoto
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
RMRikuto Masuda
Rikuto Masuda
STSorami Tani
Sorami Tani
THTomohiko Harada
Tomohiko Harada
TYTomoaki Yoshimura
Tomoaki Yoshimura
Background: Osimertinib is the standard of care for epidermal growth factor receptor mutation-positive non-small cell lung cancer, but heart failure hospitalization (HFH) remains a concern, and no practical tool exists to stratify HFH risk during therapy. Methods: In this retrospective cohort study using a Japanese claims database, 5802 patients newly initiating osimertinib were followed for HFH during treatment. Baseline predictors assessed before the index date were selected by 10-fold cross-validated least absolute shrinkage and selection operator (LASSO) logistic regression and internally validated by bootstrapping (B = 500), repeating predictor selection in each resample. Cumulative incidence functions and Fine–Gray models treated death as a competing event; cause-specific Cox models served as sensitivity analyses. Results: HFH occurred in 169 patients (2.9%) during a median on-treatment follow-up of 9.3 months, with 268 competing deaths. LASSO retained seven predictors. The apparent concordance index (C-index) was 0.731 (95% confidence interval, 0.691–0.771) and the optimism-corrected C-index 0.718. Observed incidence increased 10.2-fold across predicted-risk deciles (1.03–10.50%). Fine–Gray and Cox estimates closely matched the logistic model. Conclusions: Baseline cardiovascular vulnerability stratifies HFH risk during osimertinib therapy. The nomogram, not externally validated, is best used as a screening aid to identify patients who may benefit from intensified cardiovascular monitoring.

17 September 2026 in Drugs - Real World Outcomes
Verified
Journal Article
Open access
PDF file
THTomohiko Harada
Tomohiko Harada
Yoshihiro noguchiYoshihiro noguchi
Yoshihiro noguchi
AOAi Ohnishi
Ai Ohnishi
RMRikuto Masuda
Rikuto Masuda
TSTomoya Sugimoto
Tomoya Sugimoto
TYTomoaki Yoshimura
Tomoaki Yoshimura
Background Nivolumab was initially approved with body weight-based dosing; however, fixed-dose regimens were later adopted based on pharmacokinetic evidence supporting comparable benefit–risk profiles. Nevertheless, the acquisition cost impact of fixed dosing relative to a body weight-based counterfactual remains unclear in Japanese real-world data. Objectives The purpose of this study was to estimate drug acquisition cost differences at the index administration by comparing observed fixed-dose quantities with a simulated body weight-based counterfactual using nationwide Japanese claims data. Methods We retrospectively analyzed nationwide Japanese claims data. Fixed-dose regimens of 80, 240, 360, and 480 mg were mapped to corresponding body weight-based regimens of 1, 3, 4.5, and 6 mg/kg, respectively, and patient-specific body weight-based doses were calculated using recorded body weight. The index administration was the first nivolumab administration observed for each patient during the database observation period. Costs were estimated at the index administration using official Japanese drug prices. Sensitivity analyses examined alternative body weight measurement windows and simulated measurement error. Bootstrap resampling was used to estimate uncertainty in the median cost difference. Results Among 3243 patients, estimated drug acquisition costs based on observed fixed-dose quantities were higher than those calculated for the simulated body weight-based counterfactual at the index administration. The median cost difference was 89,540 Japanese yen (bootstrap 95% confidence interval 86,945–92,135 Japanese yen). Median costs were 311,443 and 251,750 Japanese yen for observed fixed-dose quantities and the simulated body-weight-based counterfactual, respectively. The direction of the estimated cost difference remained consistent across sensitivity analyses, although its magnitude varied across simulated body weight measurement-error scenarios. Conclusions Using real-world Japanese claims data and official drug prices, this study estimated higher acquisition costs based on observed fixed-dose quantities than those calculated for a simulated body-weight-based counterfactual at the index administration. The body-weight-based comparator was simulated for the same patients and did not represent an observed treatment group.